BioLife Solutions Net Worth
BioLife Solutions Net Worth Breakdown | BLFS |
BioLife Solutions Net Worth Analysis
BioLife Solutions' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including BioLife Solutions' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of BioLife Solutions' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform BioLife Solutions' net worth analysis. One common approach is to calculate BioLife Solutions' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares BioLife Solutions' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing BioLife Solutions' net worth. This approach calculates the present value of BioLife Solutions' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of BioLife Solutions' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate BioLife Solutions' net worth. This involves comparing BioLife Solutions' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into BioLife Solutions' net worth relative to its peers.
Enterprise Value |
|
To determine if BioLife Solutions is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioLife Solutions' net worth research are outlined below:
| BioLife Solutions had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 143.27 M. Net Loss for the year was (66.43 M) with profit before overhead, payroll, taxes, and interest of 54.07 M. | |
| BioLife Solutions currently holds about 46.55 M in cash with (12.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09. | |
| BioLife Solutions has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Biolife solutions executive sells shares worth 882,110 |
BioLife Solutions uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BioLife Solutions. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioLife Solutions' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
BioLife Solutions Target Price Consensus
BioLife target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. BioLife Solutions' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 10 | Strong Buy |
Most BioLife analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand BioLife stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of BioLife Solutions, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBioLife Solutions Target Price Projection
BioLife Solutions' current and average target prices are 27.16 and 24.43, respectively. The current price of BioLife Solutions is the price at which BioLife Solutions is currently trading. On the other hand, BioLife Solutions' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
BioLife Solutions Market Quote on 29th of November 2024
Target Price
Analyst Consensus On BioLife Solutions Target Price
Know BioLife Solutions' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioLife Solutions is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioLife Solutions backward and forwards among themselves. BioLife Solutions' institutional investor refers to the entity that pools money to purchase BioLife Solutions' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geneva Capital Management | 2024-09-30 | 865.3 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 846.6 K | Geode Capital Management, Llc | 2024-09-30 | 842.8 K | Royce & Associates, Lp | 2024-09-30 | 825.1 K | Palisade Capital Management Llc | 2024-09-30 | 821.1 K | Granahan Investment Management Inc.. | 2024-09-30 | 658.6 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 584.3 K | Gagnon Securities Llc | 2024-09-30 | 569.4 K | Bank Of America Corp | 2024-06-30 | 544.1 K | Casdin Capital, Llc | 2024-09-30 | 8.7 M | Blackrock Inc | 2024-06-30 | 5.5 M |
Follow BioLife Solutions' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.26 B.Market Cap |
|
Project BioLife Solutions' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.40) | (0.42) | |
| Return On Capital Employed | (0.19) | (0.20) | |
| Return On Assets | (0.16) | (0.17) | |
| Return On Equity | (0.20) | (0.21) |
When accessing BioLife Solutions' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures BioLife Solutions' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioLife Solutions' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in BioLife Solutions' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioLife Solutions. Check BioLife Solutions' Beneish M Score to see the likelihood of BioLife Solutions' management manipulating its earnings.
Evaluate BioLife Solutions' management efficiency
BioLife Solutions has return on total asset (ROA) of (0.0597) % which means that it has lost $0.0597 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1504) %, meaning that it created substantial loss on money invested by shareholders. BioLife Solutions' management efficiency ratios could be used to measure how well BioLife Solutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.42 in 2024. Return On Capital Employed is likely to drop to -0.2 in 2024. At this time, BioLife Solutions' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 306.7 M in 2024, whereas Intangible Assets are likely to drop slightly above 19.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.72 | 8.11 | |
| Tangible Book Value Per Share | 2.10 | 1.11 | |
| Enterprise Value Over EBITDA | (15.87) | (16.66) | |
| Price Book Value Ratio | 2.10 | 2.00 | |
| Enterprise Value Multiple | (15.87) | (16.66) | |
| Price Fair Value | 2.10 | 2.00 | |
| Enterprise Value | 717.7 M | 753.6 M |
The strategic decisions made by BioLife Solutions management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.
Enterprise Value Revenue 8.6077 | Revenue 147 M | Quarterly Revenue Growth 0.297 | Revenue Per Share 3.222 | Return On Equity (0.15) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioLife Solutions insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioLife Solutions' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioLife Solutions insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioLife Solutions Corporate Filings
8K | 20th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 1st of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
BioLife Solutions Earnings Estimation Breakdown
The calculation of BioLife Solutions' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of BioLife Solutions is estimated to be -0.069575 with the future projection ranging from a low of -0.0875 to a high of -0.05. Please be aware that this consensus of annual earnings estimates for BioLife Solutions is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.09 Lowest | Expected EPS | -0.05 Highest |
BioLife Solutions Earnings Projection Consensus
Suppose the current estimates of BioLife Solutions' value are higher than the current market price of the BioLife Solutions stock. In this case, investors may conclude that BioLife Solutions is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and BioLife Solutions' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 10 | 60.87% | -0.0175 | -0.069575 | -1.11 |
BioLife Solutions Earnings per Share Projection vs Actual
Actual Earning per Share of BioLife Solutions refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering BioLife Solutions predict the company's earnings will be in the future. The higher the earnings per share of BioLife Solutions, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.BioLife Solutions Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as BioLife Solutions, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of BioLife Solutions should always be considered in relation to other companies to make a more educated investment decision.BioLife Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact BioLife Solutions' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -0.09 | -0.0175 | 0.0725 | 80 | ||
2024-08-08 | 2024-06-30 | -0.14 | -0.5 | -0.36 | 257 | ||
2024-05-09 | 2024-03-31 | -0.28 | -0.23 | 0.05 | 17 | ||
2024-02-29 | 2023-12-31 | -0.34 | -0.3 | 0.04 | 11 | ||
2023-11-09 | 2023-09-30 | -0.37 | -0.3 | 0.07 | 18 | ||
2023-08-08 | 2023-06-30 | -0.2 | -0.23 | -0.03 | 15 | ||
2023-05-10 | 2023-03-31 | -0.21 | -0.32 | -0.11 | 52 | ||
2023-03-16 | 2022-12-31 | -0.17 | -1.15 | -0.98 | 576 | ||
2022-11-09 | 2022-09-30 | -0.17 | -0.23 | -0.06 | 35 | ||
2022-08-09 | 2022-06-30 | -0.21 | -0.06 | 0.15 | 71 | ||
2022-05-09 | 2022-03-31 | -0.25 | -0.17 | 0.08 | 32 | ||
2022-02-28 | 2021-12-31 | -0.17 | -0.37 | -0.2 | 117 | ||
2021-11-11 | 2021-09-30 | -0.09 | 0.0018 | 0.0918 | 102 | ||
2021-08-12 | 2021-06-30 | -0.07 | -0.12 | -0.05 | 71 | ||
2021-05-13 | 2021-03-31 | -0.04 | -0.03 | 0.01 | 25 | ||
2021-03-22 | 2020-12-31 | -0.02 | -0.06 | -0.04 | 200 | ||
2020-11-05 | 2020-09-30 | -0.02 | -0.08 | -0.06 | 300 | ||
2020-08-06 | 2020-06-30 | -0.04 | -0.7 | -0.66 | 1650 | ||
2020-05-14 | 2020-03-31 | -0.02 | -0.01 | 0.01 | 50 | ||
2020-03-11 | 2019-12-31 | -0.02 | 0.02 | 0.04 | 200 | ||
2019-11-12 | 2019-09-30 | 0.02 | -0.03 | -0.05 | 250 | ||
2019-08-08 | 2019-06-30 | 0.02 | 0.04 | 0.02 | 100 | ||
2019-05-09 | 2019-03-31 | 0.04 | 0.03 | -0.01 | 25 | ||
2019-03-14 | 2018-12-31 | 0.05 | 0.04 | -0.01 | 20 | ||
2018-11-08 | 2018-09-30 | 0.04 | 0.05 | 0.01 | 25 | ||
2018-08-09 | 2018-06-30 | 0.04 | 0.05 | 0.01 | 25 | ||
2018-05-10 | 2018-03-31 | -0.01 | -0.01 | 0.0 | 0 | ||
2018-03-08 | 2017-12-31 | -0.04 | -0.05 | -0.01 | 25 | ||
2017-11-09 | 2017-09-30 | -0.06 | -0.03 | 0.03 | 50 | ||
2017-08-10 | 2017-06-30 | -0.04 | -0.06 | -0.02 | 50 | ||
2017-05-11 | 2017-03-31 | -0.05 | -0.04 | 0.01 | 20 | ||
2017-03-09 | 2016-12-31 | -0.07 | -0.26 | -0.19 | 271 | ||
2016-11-10 | 2016-09-30 | -0.08 | -0.08 | 0.0 | 0 | ||
2016-08-11 | 2016-06-30 | -0.08 | -0.11 | -0.03 | 37 | ||
2016-05-12 | 2016-03-31 | -0.08 | -0.1 | -0.02 | 25 | ||
2016-02-25 | 2015-12-31 | -0.1 | -0.09 | 0.01 | 10 | ||
2015-11-12 | 2015-09-30 | -0.1 | -0.09 | 0.01 | 10 | ||
2015-08-06 | 2015-06-30 | -0.1 | -0.08 | 0.02 | 20 | ||
2015-05-07 | 2015-03-31 | -0.09 | -0.09 | 0.0 | 0 | ||
2015-03-12 | 2014-12-31 | -0.07 | -0.08 | -0.01 | 14 | ||
2014-11-06 | 2014-09-30 | -0.05 | -0.07 | -0.02 | 40 | ||
2014-08-07 | 2014-06-30 | -0.04 | -0.07 | -0.03 | 75 | ||
2014-05-08 | 2014-03-31 | -0.04 | -0.1004 | -0.0604 | 151 |
BioLife Solutions Corporate Management
| Sarah JD | Chief Officer | Profile | |
| Troy Wichterman | Chief Officer | Profile | |
| Geraint Phillips | Senior Operations | Profile | |
| Troy CPA | Chief Officer | Profile |
Additional Tools for BioLife Stock Analysis
When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.